# Addition of Thoracic Consolidation Radiotherapy to the Maintenance Immunotherapy for ES-SCLC (STONE-001)

Source: https://onco.cc/trials/nct06719336/  
OnCo record `nct06719336` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial in lung cancer, run by Anhui Shi, MD, not yet recruiting.

## Summary

Addition of Thoracic Consolidation Radiotherapy to the Maintenance Immunotherapy for ES-SCLC (STONE-001) is a phase 3, randomised interventional study registered as NCT06719336 by Anhui Shi, MD, with a registry enrolment figure of 182 participants, started 2024-12-16 and due to reach its primary completion in 2028-12-16. Interventions recorded: High-dose Hyperfractionated Simultaneous Integrated Boost Radiotherapy; atezolizumab or durvalumab. Conditions listed: Extensive-stage Small Cell Lung Cancer. Primary outcome: Overall survival (OS). Lung eligibility wording from the registry: "Confirmed Extensive Stage Small Cell Lung Cancer (ES-SCLC)". No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: planned
- Last checked: 2026-09-25
- Tags: ctgov-ingest; lung-deep-dive
- Registry id: NCT06719336
- Phase: 3
- Setting: Addition of High-dose Hyperfractionated Simultaneous Integrated Boost Radiotherapy to the Maintenance Therapy with PD-L1 Inhibitor Versus PD-L1 Inhibitor Alone for Extensive Stage Small Cell Lung Cancer (STONE-001)
- Sponsor: Anhui Shi, MD
- Enrolled: 182

## Sources

- ClinicalTrials.gov NCT06719336: https://clinicaltrials.gov/study/NCT06719336

## Connected records

- cancers: [Extensive-stage small-cell lung cancer](https://onco.cc/cancers/extensive-stage-sclc/)
- technologies: [IMRT / IGRT (modern external beam)](https://onco.cc/technologies/imrt-igrt/)
- terms: [Lung cancer trials open today (registry snapshot)](https://onco.cc/terms/lung-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct06719336.json